Posted on 2/28/17
Better Buy: PDL BioPharma, Inc. vs. Johnson & Johnson
Biotech finance specialist PDL Biopharma (NASDAQ:PDLI) has been suffering a prolonged market thrashing that's driven its stock price down about 75% over the past three years. . . .
Posted on 2/28/17
Ortho Clinical Diagnostics Awarded Top Honor for Global Excellence in Customer Service
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that it has been awarded the Gold Stevie Award for Global Customer Service . . .
Posted on 2/27/17
Johnson & Johnson Completes Acquisition of Abbott Medical Optics
Johnson & Johnson (NYSE: JNJ) today announced it has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott.
Posted on 2/27/17
Upcoming Events: J&J And NeuroDerm Put New Delivery Routes To The Test
Welcome to your weekly digest of approaching regulatory and clinical readouts. In the coming months phase III data are expected from Johnson & Johnson's (NYSE:JNJ) antidepressant . . .
Posted on 2/27/17
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
When it comes to safe stocks, there may be none safer than healthcare conglomerate Johnson & Johnson (NYSE:JNJ). Johnson & Johnson is often a staple holding . . .
Posted on 2/27/17
Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc
A couple recent events helped shares of Eli Lilly and Co (NYSE:LLY) bounce back from a big clinical trial failure that sent the stock tumbling late . . .
Posted on 2/27/17
These 3 Big Pharma Stocks Are Ridiculously Cheap
It's not the easiest of task to find large biopharmaceutical companies with stocks trading at low valuations. But there are some relatively inexpensive alternatives out there.Teva . . .
Posted on 2/27/17
Warren Buffett's Bet On This Bank Quadrupled in Just 6 Years
Warren Buffett may not have supported Donald Trump's candidacy for president, but the 86-year-old billionaire certainly benefited from the unexpected outcome.Stocks are up across the board . . .
Posted on 2/24/17
Is Pfizer's Research Pipeline Truly Undervalued?
In my previous articles, I have discussed my expectations related to the impact of changing tax reforms on Pfizer (NYSE:PFE). I have also given a detailed . . .
Posted on 2/24/17
Celgene: A 'Fuggedaboutit' Core Biotech Holding
Celgene (NASDAQ:CELG) has been a "core" position within the model 20-stock Biotech Forum portfolio for quite some time. Although the stock is more expensive than some . . .
Posted on 2/24/17
Here's Why Celgene's Latest Drug Is So Exciting
Celgene (NASDAQ:CELG) recently reported that its multiple sclerosis drug, ozanimod, successfully met its endpoints in reducing multiple sclerosis (MS) relapses, and assuming a second trial pans . . .
Posted on 2/23/17
New Jersey Plastic Surgeons Introduce Non-Surgical Facelift Alternative
Dr. John T. Cozzone and Dr. Luis A. Zapiach are committed to remaining up-to-date with the latest developments in plastic surgery technology and techniques. At their . . .
Posted on 2/23/17
Governor Christie and other Dignitaries Join Victory Bay Recovery Center for a Ribbon-Cutting
Victory Bay Recovery Center will proudly celebrate the opening of its state-of-the-art substance abuse treatment facility with a ribbon cutting on Thursday, March 2, 2017 at . . .
Posted on 2/22/17
HealthSTAR Communications Expands its Strategic Offerings with Launch of HealthSTAR Fusion Group
MAHWAH, N.J.--(BUSINESS WIRE)--HealthSTAR Communications, a leading independent healthcare marketing services company, today announced the launch of HealthSTAR Fusion Group, an important new addition to its strategic . . .
Posted on 2/22/17
Symbiomix Therapeutics Appoints David L. Stern as CEO
Symbiomix today announced it has hired David L. Stern, MBA, a seasoned biopharmaceutical executive with over
Posted on 2/22/17
Better Buy: Pfizer Inc. vs. Merck & Co. Inc.
Investors have really liked Merck (NYSE:MRK) stock over the last 12 months, with shares jumping around 30%. Pfizer (NYSE:PFE) has performed pretty well also, but not . . .
Posted on 2/22/17
AGS Health Named to the 2017 Global Outsourcing 100 List
AGS Health Inc., a global healthcare revenue cycle management company has been named for the fifth year in a row to the prestigious 2017 Global Outsourcing . . .
Posted on 2/22/17
MetroPlus Health Plan Announces New Member Engagement and Rewards Program
NEW YORK--(BUSINESS WIRE)--MetroPlus Health Plan announced today the introduction of its member engagement and rewards program. The MetroPlus Healthy Rewards Program is designed to engage members . . .
Posted on 2/21/17
Four Amsterdam Dental Group Specialists Named Philadelphia Magazine’s Top Dentists 2017 – Prosthodontics
Amsterdam Dental Group, a leader in periodontal prosthesis and periodontics, is pleased to announce four of its dual-trained dental specialists have been named Philadelphia Magazine’s Top . . .
Posted on 2/21/17
Pfizer Near A Technical Breakout
Pfizer (NYSE:PFE) has been gaining a lot of momentum recently with its share price having risen almost 7% since the 24th of January. The stock has . . .
Posted on 2/21/17
Pfizer Is A Solid Buy In 2017
In my previous article, I explained why I felt the new Trump administration may be a positive for Pfizer (NYSE:PFE). But an investor need not only . . .
Posted on 2/21/17
Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?
A new and highly anticipated study by Celgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. . . .
Posted on 2/21/17
Better Buy: Eli Lilly and Company vs. Johnson & Johnson
Eli Lilly and Company (NYSE:LLY) ranks as one of the largest drugmakers on the planet. But Lilly looks relatively small when compared to Johnson & Johnson . . .
Posted on 2/21/17
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Your time horizon is important when comparing the performance of different stocks. Gilead Sciences (NASDAQ:GILD), for example, handily beat Pfizer (NYSE:PFE) over the past five years. . . .
Posted on 2/21/17
A Billionaire Recently Bought Pfizer Stock -- and So Did I
If you combined hedge fund investor David Tepper's net worth with mine, you'd have around $11 billion. Of course, Tepper is a multibillionaire ranked as one . . .

